Pablo Matar

Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

Pablo Matar, Federico Rojo, Raúl Cassia et al. · Clinical Cancer Research · 2004 · 277 citations · Full text

Medicine, Oncology, Pharmacology +16

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Judit Anido, Pablo Matar, Joan Albanell et al. · PubMed · 2003 · 249 citations

Medicine, Oncology, Pharmacology +17

Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model

Pablo Matar, Viviana R. Rozados, Silvia Gervasoni et al. · Cancer Immunology Immunotherapy · 2002 · 119 citations · Full text

Medicine, Immunology, Pharmacology +13

Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response

Laura Alaniz, Miguel Rizzo, Mariana Malvicini et al. · Cancer Letters · 2009 · 59 citations

Medicine, Immunology, Oncology +14

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity

V. R. Rozados, Alberto Morant Sánchez, Silvia Gervasoni et al. · Annals of Oncology · 2004 · 56 citations · Full text

Medicine, Oncology, Pharmacology +11